

# MicroRNAs as biomarkers in Oral Cancer: Literature Review

Rodrigues, C.A. <sup>\*1,2</sup>, Palmeira, C. <sup>1,2</sup>, Santos, J.M.O. <sup>3</sup>, de Sousa, P.V. <sup>1,2</sup>, Lara-Santos, L. <sup>1,2</sup>

<sup>1</sup>Faculty of Health Sciences, Fernando Pessoa University (FCS-UPF), Porto, Portugal

<sup>2</sup>Pathology and Experimental Therapy Group, Research Centre of Portuguese Oncology Institute Francisco Gentil (CI-IPOP-FG), Porto, Portugal

<sup>3</sup>Molecular Oncology and Viral Pathology Group, Research Centre of Portuguese Oncology Institute Francisco Gentil (CI-IPOP-FG), Porto, Portugal



## INTRODUCTION

Oral cancer (OC) is a form of head and neck cancer and it's the sixth most common type of cancer worldwide. OC may be preceded by oral lesions that have higher risk of malignant transformation (OPML). Oral squamous cell carcinoma (OSCC) is the most common cancer type arising in the oral cavity.

Early diagnosis of OC is extremely important for treatment and patients' survival. Hence, research directed towards the identification of biomarkers for early diagnosis of OSCC and indicators of good or bad prognosis is undeniably essential.


MicroRNAs (miRs/miRNAs) are endogenous small (18-25 ribonucleotides) noncoding RNAs that negatively regulate gene expression at posttranscriptional level. Many recent studies have shown deregulated expression of miRs in OSCC, indicating their potential role in oral cancer development (Fig.1) and their use as diagnosis and prognosis biomarkers for this disease.

## AIM

The aim of this research was to investigate the role of miRs in oral cancer, showing some of the most deregulated, as well their potential as biomarkers for early diagnosis and prognosis in this malignancy.

## MATERIALS AND METHODS

The research strategy was performed using the PubMed/Medline electronic database, using the keywords "microRNA", "biomarkers" and "oral cancer" and the Boolean operator "AND". Inclusion criteria included studies with human samples, published in the last 10 years (2009-2019) and in English. The exclusion criteria consisted in studies using cell lines or other animals, in other language besides English and without available abstract. 255 studies were found and after reading the title and the abstract, 190 were excluded. 65 studies were selected for full-text analysis, and 12 met the inclusion and exclusion criteria.



## RESULTS

Study	OPML studied	Number of samples (Controls/OPML/OC)	Type of sample	miR investigated	Sensitivity/ Specificity/ AUC (OPML)	Results
Zahran et al. (2015)	OPML not defined But divided in with dysplasia (OPML-D) and without dysplasia (OPML-ND)	80 (20/20+20/20)	Saliva	miR-184	80%/ 75%/ 0,86	miR-21 and miR-184 overexpressed in OC and OPML-D. miR-145 underexpressed in OC and OPML-ND.
				miR-145	60%/ 70%/ 0,68	
				miR-21	65%/ 65%/ 0,73	
Brito et al. (2013)	Oral leukoplakia (OL) with different grades of dysplasia	45 (6/22/17)	Tissue	miR-21	ND	miR-21 and miR-345 overexpressed in OC and OL. miR-181b overexpressed in OC and in OL with moderate/severe dysplasia.
				miR-345		
				miR-181b		
Lu et al. (2014)	Hyperkeratosis (HK), parakeratosis (PK), squamous hyperplasia (SH), verrucous hyperplasia (VH)	159 (53/16/90)	Plasma	miR-196a	56%/ 94%/ 0,76	miR-196a and miR-196b overexpressed in OC and OPML.
				miR-196b	100%/ 59%/ 0,84	
Arão et al. (2012)	Oral Lichen Planus (OLP)	37 (6/31/0)	Tissue	miR-146a	ND	miR-146a and miR-155 overexpressed in OC and OLP.
				miR-155		
Roy et al. (2016)	Oral leukoplakia (OL), Oral Lichen Planus (OLP)	80 (20/20+20/20)	Tissue	miR-26a	ND	All miRs were overexpressed in OLP tissues. miR-29a and miR-26a underexpressed in OC and in OL.
				miR-29a		
				miR-34b		
				miR-423		
Hung et al. (2016)	OPML not defined	44 (24/20/0)	Saliva	miR-31	AUC= 0,81	miR-21 and miR-31 overexpressed in saliva of patients with OLPM.
				miR-21	AUC=0,56	

Study	Number of samples (Controls/OC)	Type of sample	miR investigated	miR expression in OC	Sensitivity/ Specificity/ AUC (OC)	Role of miR deregulation in oral carcinogenesis
Liu et al. (2010)	64 (21/43)	Plasma and saliva	miR-31	Overexpression	AUC = 0,82	Induces tumor initiation and progression
Sun et al. (2016)	144 (40/104)	Serum	miR-9	Underexpression	ND	Increases tumor growth and metastasis
Ren et al. (2014)	90 (32/58)	Blood	miR-21	Overexpression	62%/ 91%/ 0,79	Promotes tumor migration and invasion
Sasahira et al. (2012)	128 (10/118)	Tissue	miR-126	Underexpression	ND	Induces angiogenesis
Yang et al. (2011)	51 (12/39)	Plasma and tissue	miR-181a	Overexpression	AUC= 0,84	Increases metastasis and vascular invasion
			miR-181b		AUC= 0,74	
Xu, et al. (2016)	204 (103/101)	Serum	miR-483-5p	Overexpression	85%/ 75%/ 0,85	Increases metastasis and tumor differentiation

## CONCLUSION

Although a large number of studies are based on tissue samples, for early diagnosis, non-invasive collection techniques and easily accessed samples are essential. Since they have direct contact with oral lesions, are easy to collect and their use is well accepted by patients, saliva and oral exfoliative cytology represent effective samples for miRs' detection. miRs have characteristics that classify them as ideal tumor markers, such as their stability at high temperatures and extreme pH values, the ease in their detection and their association with clinical-pathological parameters.

miR-21, miR-31 and miR-181 seem to be closely related with OC and with the malignant transformation of oral lesions.

However, there are still some limitations, such as the lack of standardization of sample processing and intra-tumor heterogeneity, which condition their progress as clinical tool.

Therefore, more studies and research are needed before their generalized use in the clinical field.

## CLINICAL IMPLICATIONS

Dentists have a key role in early detection of oral malignant lesions and monitoring conditions with high risk of malignant transformation. Studies regarding miRs show positive perspectives for their use in clinical practice, for diagnosis and prognosis of OC and OPML. Therefore, clinicians should have knowledge about miRs and be aware of new tools based on these molecules.

## REFERENCES:

- Irimie, A. I. et al. (2017). A looking-glass of non-coding RNAs in oral cancer. International Journal of Molecular Sciences, 18(12), 1–28.  
 Zahran, F. et al. (2015). Salivary microRNAs in oral cancer. Oral Diseases, 21(6), 739–747.  
 Brito, J. A. R. et al. (2013). Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia. Journal of Oral Pathology & Medicine, 43(3), 211–216.  
 Lu, Y. C. et al. (2015). Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clinical Biochemistry, 48(3), 115–121.  
 Arão, T. C. et al. (2011). Increased miRNA-146a and miRNA-155 expressions in oral lichen planus. Archives of Dermatological Research, 304(5), 371–375.  
 Roy, R. et al. (2016). MicroRNA and target gene expression based clustering of oral cancer, precancer and normal tissues. Gene, 593(1), 58–63.  
 Hung, K.F. et al. (2016). MicroRNA-31 upregulation predicts increased risk of progression of oral potentially malignant disorder. Oral Oncology, 53, 42–47.  
 Sun, L. et al. (2016). Association of Decreased Expression of Serum miR-9 with Poor Prognosis of Oral Squamous Cell Carcinoma Patients. Medical Science Monitor, 22, pp. 289–294.  
 Liu, C. et al. (2010). Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Diseases, 16(4), pp. 360–364.  
 Ren, W. et al. (2014). Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma. Biomarkers, 19(7), 590–596.  
 Sasahira, T. et al. (2012). Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. British Journal of Cancer, 107(4), 700–706.  
 Yang, C. et al. (2011). miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. Journal of Oral Pathology & Medicine, 40(5), 397–404.